open access

Vol 3, No 4 (2007)
Case report
Published online: 2007-07-27
Get Citation

Diagnostic and therapeutic quandaries in NK-cell lymphomas - a report of two cases

Monika Chełstowska, Ewa Kalinka-Warzocha, Ewa Mendek-Czajkowska, Piotr Centkowski, Maria Błasińska-Morawiec, Krzysztof Warzocha
Onkol. Prak. Klin 2007;3(4):217-222.

open access

Vol 3, No 4 (2007)
CASE REPORTS
Published online: 2007-07-27

Abstract

In the present paper we describe clinical course of natural killer (NK) cell lymphomas. In the first patient, diagnosis of nasal NK/T cell lymphoma was based on histopathologic examination of tumor lesion within the base of nose (Ann Arbor IIA). The patient received chemotherapy according to CN3OP (cyclophosphamide, mitoxantrone, vincristine, prednisone) and IVAC (etoposide, ifosfamide, cytarabine) protocols. His initial response to chemotherapy was good, but rapid disease progression within skin and lungs subsequently occured. The patient died due to cardio-pulmonary insufficiency 7 months after lymphoma diagnosis. In the second patient, diagnosis of blastic NK cell lymphoma was based on histopathologic findings in skin and trephine biopses. The patient was treated according to COP (cyclophosphamide, vincristine, prednisone) and CC (cyclophosphamide, cladribine) protocols and after disease progression he received 2 additional courses of mitoxantrone, etoposide and cytarabine. His initial response to chemotherapy was good, but rapid disease progression within bone marrow and skin occured. The patient zajmowadied due to central nervous system hemorrhage in the course of disseminated intravascular coagulopathy 9 months after lymphoma diagnosis. These two case reports reveal diagnostic and therapeutic difficulties of the very rare NK cell lymphomas.

Abstract

In the present paper we describe clinical course of natural killer (NK) cell lymphomas. In the first patient, diagnosis of nasal NK/T cell lymphoma was based on histopathologic examination of tumor lesion within the base of nose (Ann Arbor IIA). The patient received chemotherapy according to CN3OP (cyclophosphamide, mitoxantrone, vincristine, prednisone) and IVAC (etoposide, ifosfamide, cytarabine) protocols. His initial response to chemotherapy was good, but rapid disease progression within skin and lungs subsequently occured. The patient died due to cardio-pulmonary insufficiency 7 months after lymphoma diagnosis. In the second patient, diagnosis of blastic NK cell lymphoma was based on histopathologic findings in skin and trephine biopses. The patient was treated according to COP (cyclophosphamide, vincristine, prednisone) and CC (cyclophosphamide, cladribine) protocols and after disease progression he received 2 additional courses of mitoxantrone, etoposide and cytarabine. His initial response to chemotherapy was good, but rapid disease progression within bone marrow and skin occured. The patient zajmowadied due to central nervous system hemorrhage in the course of disseminated intravascular coagulopathy 9 months after lymphoma diagnosis. These two case reports reveal diagnostic and therapeutic difficulties of the very rare NK cell lymphomas.
Get Citation

Keywords

lymphoma; natural killer cells; diagnosis; treatment; prognosis

About this article
Title

Diagnostic and therapeutic quandaries in NK-cell lymphomas - a report of two cases

Journal

Oncology in Clinical Practice

Issue

Vol 3, No 4 (2007)

Article type

Case report

Pages

217-222

Published online

2007-07-27

Bibliographic record

Onkol. Prak. Klin 2007;3(4):217-222.

Keywords

lymphoma
natural killer cells
diagnosis
treatment
prognosis

Authors

Monika Chełstowska
Ewa Kalinka-Warzocha
Ewa Mendek-Czajkowska
Piotr Centkowski
Maria Błasińska-Morawiec
Krzysztof Warzocha

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl